Search 

novel IO Ab therapeutics

Since 1989, at ferropharma we are changing the health care market by cutting value chains to decrease cost of drug development and drug availability.
One of our brand, EMELEMA® - Making Latest Medicine Available – is what we believe in and what drives the best talent from around the globe to join us.  
Our aim is to be known as the company that increases patient access to generic and innovative medicine. We focus on building bridges between markets, stakeholders and patients. Collectively, we believe in finding the most fair, straight and reliable provider for the distribution of Active Pharmaceutical Ingredients (API), Finished Dosage Forms (FDF) and services. Thanks to our dedicated teams in Brazil, China, Germany, India and Malta, we are using manufacturing plants for high quality products, in the most efficient way. We direct our attention on novel delivery systems and the provision of EU registered and manufactured drugs..
We made quality our priority. The EMA, FDA and ANVISA standards for APIs and FDFs are our benchmarks that we fulfill.
We operate worldwide but our core markets are China, Latin America and the European Union.

Life science-focused Innovation licensing organizations looking to commercialize global innovations for the Indian and South Asian markets through a unique partnership-led model.

We are leaders in therapeutic target discovery and RNA-targeted therapies in Cardiovascular Disease (CVD). Our technology platforms seamlessly integrate synergistically to accelerate development of therapies to treat illnesses where no other treatments have proven effective or ever existed.
We have developed a rich pipeline of therapeutics, including RNAi and NCE's for heart failure, cardiotoxicity, cardiac regeneration and rare cardiometabolic disease.

Huahai Investment Co, Ltd is a young, China-based firm backed by the Huahai Pharmaceuticals Group, a listed company in the Shanghai Stock Exchange. Our twin missions are to make investment as well as partnership deals in the healthcare sector.

Idience Co. Ltd. (“Idience’) is a NRDO (No Research & Development Only) company focusing on oncology treatment. The company was established in 2019 by Ildong Holdings Group, a holding company of leading pharmaceutical and healthcare companies in South Korea.

Our first asset, IDX-1197 is a PARP inhibitor for various solid cancers including breast cancer and ovarian cancer. Its ongoing Phase 1a multi-center study showed a promising result. In October 2019, Idience received approval for its initial Investigational New Drug (IND) application from the Korea Ministry of Food and Drug Safety to start a Phase 1b/2a clinical trial for IDX-1197.

Idience is looking for corporate partners to discover and develop oncology therapeutics. We are open to all license-in and license-out partners.

University of Calgary based accelerator

Next Pharma Inc. (NPI) is a biotechnology company headquartered in Toronto, Canada, focused on developing and commercializing products for early detection, diagnosis, and monitoring of the recurrence of Cancer and COVID-19 disease.
NPI is headquartered in Toronto, Ontario, Canada and will globally distribute and commercialize its AABH based diagnostic tests. NPI’s diagnostic tests are regarded as revolutionary as they can help to diagnose cancer at an early stage using a blood serum with high sensitivity/high specificity, fast turnaround (within 7 hours), are relatively inexpensive and are non-invasive.